Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Sep 9;22(2):398–406. doi: 10.1038/s41436-019-0651-6

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license. You do not have permission under this license to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

PMC Copyright notice

Fig. 2 — Breast cancer survival and risk of contralateral breast cancer.a Contralateral breast cancer incidence after the first breast cancer in female patients with neurofibromatosis 1 (NF1) compared with screened family history clinic patients without NF1. b All-cause survival in unscreened patients with NF1 compared with screened family history clinic patients without NF1. The numbers of patients at risk at different time points are shown in Table 1. c Breast cancer–specific survival in unscreened patients with NF1 compared with screened family history clinic patients without NF1. The numbers of patients at risk at different time points are shown in Table 2. d All-cause survival in patients with NF1 (screened and unscreened) compared with screened family history clinic patients without NF1 stratified by tumor grade. The follow-up of patients with NF1 starts either at the first breast cancer, or the latter of the first breast cancer and entry to NF1 cohort (delayed entry). Early screening in the non-NF1 group consists of annual mammography at 30–49 years of age and 18-monthly screening at 50–59 years of age.